WCMNY
TLSI icon

Westchester Capital Management (New York)’s TriSalus Life Sciences TLSI Stock Holding History

Westchester Capital Management (New York)’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-414,265
Closed -$4.11M – 450
2022
Q3 		$4.11M Hold
414,265
– – 0.12% 198
2022
Q2 		$4.08M Hold
414,265
– – 0.11% 179
2022
Q1 		$4.06M Sell
414,265
-101,423
-20% -$1M 0.11% 181
2021
Q4 		$5.1M Buy
+515,688
New +$5.12M 0.14% 102

Other funds holding TLSI

MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
DFCM
Dark Forest Capital Management San Juan, Puerto Rico $1.13B AUM 18.74% 1-Year Est. Return
SIA
SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Westchester Capital Management (New York)'s TLSI Position: Q4 2022 in Review

Westchester Capital Management (New York) sold out of TriSalus Life Sciences (TLSI) in Q4 2022, closing a stake of 414,265 shares — an estimated $4.11M sold.

Westchester Capital Management (New York) first reported a position in TLSI in Q4 2021 and held it in 4 quarters. The position peaked at $5.1M in Q4 2021. 9 funds tracked by Wall St. Rank hold TLSI as of Q4 2022.

  • Westchester Capital Management (New York) reported no remaining TriSalus Life Sciences position as of Q4 2022 after selling out during the quarter.
  • Westchester Capital Management (New York) sold 414,265 TriSalus Life Sciences shares in Q4 2022, an estimated $4.11M.
  • Westchester Capital Management (New York) first reported a position in TriSalus Life Sciences in Q4 2021 and held it in 4 quarters.
  • Westchester Capital Management (New York)'s TriSalus Life Sciences position peaked at $5.1M in Q4 2021.
  • 9 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q4 2022.

Based on Westchester Capital Management (New York)'s 13F filing for Q4 2022, filed 14 Feb 2023.